Daiichi Sankyo Company Limited (D4S MU) stock market data APIs
€15.8696
0(0%)
as of March 20, 2026
Try our APIs with
free plan!
Daiichi Sankyo Company Limited Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for D4S.MU.
Prev. Close
15.8696
Open
15.8696
High
15.8696
Low
15.8696
52 wk Range
15.315-23.7283
Market Cap
38 045 M
Dividends (Yield)
0.5932
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Daiichi Sankyo Company Limited data using free add-ons & libraries
Get Daiichi Sankyo Company Limited Fundamental Data
Daiichi Sankyo Company Limited Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Daiichi Sankyo Company Limited News
New
Daiichi Sankyo Deepens Biologics Push As ENHERTU Faces FDA Decision
Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Daiichi Sankyo (TSE:4568) e...
Is Now The Right Time To Reassess Daiichi Sankyo (TSE:4568) After Recent Share Price Weakness?
Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Investors may be wondering whether Daiichi Sankyo Company i...
Leveragen Announces Collaboration with Daiichi Sankyo to Support Development of Advanced Biologics Using Next-Gen In Vivo Antibody Discovery Platforms
Under the collaboration, Daiichi Sankyo will work with Leveragen to apply Leveragen’s in vivo antibody discovery capabilities in support of selected research programs. The collaboration reflects a s...
Voro Therapeutics Announces Research Collaboration with Daiichi Sankyo to Advance PrimeBody™ Technology for Next-Generation Tumor-Activated ADCs
Collaboration will leverage Voro's PrimeBody platform to advance tumor-activated antibody drug conjugates designed to expand therapeutic index and enhance precision targeting SAN DIEGO, March 17, 202...
Get Daiichi Sankyo Company Limited fresh news feed via Financial News API
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
